

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/155925 A1

(51) International Patent Classification:

C07K 16/32 (2006.01) C12N 15/02 (2006.01)
C07K 16/30 (2006.01) A61K 39/395 (2006.01)
C07K 16/46 (2006.01) A61P 35/00 (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:

PCT/CN2023/077493

(22) International Filing Date:

21 February 2023 (21.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/077113

21 February 2022 (21.02.2022) CN

(71) Applicant: **CONCEPT TO MEDICINE BIOTECH CO., LTD.** [CN/CN]; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN).

(72) Inventors: **LIU, Fang**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN). **GONG, Wenci**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN). **CAI, Zhijian**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN). **YANG, Liu**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN). **GAO, Shan**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN). **JIANG, Wenqing**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN). **FANG, Lei**; Floor 3, Building 4, No. 651 Lianheng Road, Pujiang, Minhang District, Shanghai 201112 (CN).

(74) Agent: **SHANGHAI BESHINING LAW OFFICE**; 21st Floor, SFECO Mansion 681 Xiaomujiao Road, Xuhui District, Shanghai 200032 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

WO 2023/155925 A1

(54) Title: ANTI-5T4 ANTIBODIES AND USES THEREOF

(57) Abstract: This disclosure provides anti-5T4 antibodies, variants thereof and humanized versions. The newly disclosed antibodies exhibited high affinity to the 5T4 protein and can be used to treat cancers.